Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
R-CHOP + RT in Limited-Stage Aggressive NHL
NCT00005089Phase 2Completed
- Sponsor
- SWOG Cancer Research Network
- Start
- Apr 2000
- Primary completion
- Nov 2004
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of rituximab in non-Hodgkin lymphoma (NHL), diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), Burkitt lymphoma (BL), anaplastic large cell lymphoma (ALCL), sponsored by SWOG Cancer Research Network. Started Apr 2000; status: completed.
02
Drugs
rituximab
03
Conditions
non-Hodgkin lymphoma (NHL)diffuse large B-cell lymphoma (DLBCL)mantle cell lymphoma (MCL)Burkitt lymphoma (BL)anaplastic large cell lymphoma (ALCL)
Beyond the preview
Go deeper on NCT00005089.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00005089.